Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, et al. Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination. J Clin Oncol 2022 Jul 22:JCO2200221. doi: 10.1200/JCO.22.00221.
PMID: 35867951